問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

Division of Hematology & Oncology

Digestive System Department

Division of Hematology & Oncology

Division of General Surgery

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

陳佳宏
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

87Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳佳宏

List

155Cases

2016-08-08 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2018-03-01 - 2019-09-30

Others

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer, NSCLC

  • Test Drug

    G1T38

Participate Sites
10Sites

Terminated9Sites

2020-10-20 - 2022-04-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2014-05-01 - 2018-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-09-01 - 2022-08-31

Phase I

A PHASE 1 DOSE FINDING/EXPANSION STUDY OF HLX55, A MONOCLONAL ANTIBODY TARGETING TYROSINEPROTEIN KINASE MET (C-MET) IN PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY

  • Condition/Disease

    solid tumor

  • Test Drug

    HLX55

Participate Sites
4Sites

Recruiting4Sites

2016-01-06 - 2019-06-30

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN

  • Condition/Disease

    RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

  • Test Drug

    PD-0332991

Participate Sites
6Sites

Terminated6Sites

2017-09-21 - 2020-12-31

Phase III

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

  • Condition/Disease

    Advanced Breast Cancer

  • Test Drug

    Ribociclib (LEE011)/ Letrozole/Goserelin

Participate Sites
6Sites

Terminated5Sites

鍾為邦
National Taiwan University Hospital

Division of Hematology & Oncology

邱昌芳
China Medical University Hospital-Taipei

未分科

2019-02-28 - 2023-04-30

Phase II

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Breast cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting8Sites

劉良智
China Medical University Hospital-Taipei

未分科

陳訓徹
Linkou Chang Gung Medical Foundation

2015-06-25 - 2018-01-09

Phase III

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin ®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

  • Condition/Disease

    NSCLC

  • Test Drug

    PF-06439535

Participate Sites
6Sites

Study ended5Sites

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

  • Condition/Disease

    Untreated Advanced Gastric and Gastroesophageal Cancer

  • Test Drug

    FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源
China Medical University Hospital-Taipei

未分科

1 12 13 14 15 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB